# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Citigroup analyst Yigal Nochomovitz initiates coverage on Summit Therapeutics (NASDAQ:SMMT) with a Buy rating and announces ...
Summit Therapeutics (NASDAQ:SMMT) reported quarterly losses of $(0.06) per share. This is a 95.8 percent increase over losses o...
- SEC Filing